AND S I SOUS THE

16 5 2 P

CERTIFICATE OF MAILING

Neereby certify that this paper (along with any paper referred to as being attached or enclosed) is being deposited with the United States Postal Service on the date shown below with sufficient postage as first class mail in an envelope addressed to the: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Keith R. Lange

Type or print name

Signature

November 20, 2003

Date

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF

C. PATRICK MCATEE

APPLICATION NO: 10/045,202

FILED: OCTOBER 22, 2001

FOR: MODULATORS OF BRUTON'S TYROSINE KINASE AND

BRUTON'S TYROSINE KINASE INTERMEDIATES AND METHODS FOR THEIR IDENTIFICATION AND USE IN THE TREATMENT AND PREVENTION OF OSTEOPOROSIS AND RELATED DISEASE

STATES

Mail Stop DD Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

FEE LETTER FOR INFORMATION DISCLOSURE STATEMENT

Sir:

Please charge Deposit Account No. 19-3880 in the name of Bristol-Myers Squibb Company in the amount of \$180 for payment of the fee pursuant to 37 CFR §1.17(p) for the submission of an Information Disclosure Statement under 37 CFR §1.97(c).

An additional copy of this paper is here enclosed. The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment, to Account No. 19-3880 in the name of Bristol-Myers Squibb Company.

Respectfully submitted,

Bristol-Myers Squibb Company Patent Department P.O. Box 4000 Princeton, NJ 08543-4000 (609) 252-3883

Date: November 20, 2003

Keith R. Lange Attorney for Applicant Reg. No. 44,201 MOV 2 2003 W

CERTIFICATE OF MAILING

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being deposited with the United States Postal Service on the date shown below with sufficient postage as first class mail in an envelope addressed to the: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22\$13-1450.

Keith R. Lange

Type or print name

Signature

November 20, 2003

Date

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF

C. PATRICK MCATEE

APPLICATION NO: 10/045,202

FILED: OCTOBER 22, 2001

FOR: MODULATORS OF BRUTON'S TYROSINE KINASE AND

BRUTON'S TYROSINE KINASE INTERMEDIATES AND METHODS FOR THEIR IDENTIFICATION AND USE IN THE TREATMENT AND PREVENTION OF OSTEOPOROSIS AND RELATED DISEASE

STATES

Mail Stop DD' Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Sir:

In accordance with 37 C.F.R. §1.56, applicant wishes to call the Examiner's attention to the references cited on the attached form(s) PTO-1449.

These references were cited in a search report in a corresponding PCT International application. Copies of these references and the search report are enclosed herewith.

The Examiner is requested to consider the foregoing information in relation to this application and indicate that each reference was considered by returning a copy of the initialed PTO 1449 form(s).

12/01/2003 WASFAW1 00000007 193880 10045202

01 FC:1806

180.00 DA

Respectfully submitted,

Bristol-Myers Squibb Company Patent Department P.O. Box 4000 Princeton, NJ 08543-4000 (609) 252-3883

Date: November 20, 2003

Keith R. Lange Attorney for Applicant Reg. No. 44,201

FORM PTO-1449 (REV. 7-85) U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

ATTY. DOCKET NO. D0032 NP APPLICATION NO. 10/045,202 APPLICANT C. Patrick McAtee FILING DATE OCTOBER 22, 2001

| | 50 P E 200 | 3 20 | FILING DATE OCTOBER 22, 2001 | | | | | | Group | | |
|-----|-------------|------|------------------------------|----------|-------------------|-----|------|----------|-------|----------------|--|
| PAR | HUI | | U.S. PATENT DOCUMENTS | | | | | | | | |
| | EXAMINER NO | av | DOCUMENT NUMBER | DATE | NAME | | CLA | SS SUBCL | ASS F | ILING DATE | |
| | | AA | | | | | | | | | |
| | | AB | | | | | | | | | |
| | | AC | | | | | | | | | |
| | | AD | | | | | | | | _ | |
| | | AE | |] | | | | | | | |
| | | AF | | | | | | | | | |
| | | AG | | | | - ' | | | | | |
| | | АН | | | | | | | | | |
| | | Al | | | | | | | | | |
| | | AJ | | | | | | | | | |
| | , | AK | | | | | | | | | |
| | | AL | | | | | | | | | |
| | | | | FOREIG | N PATENT DOCUMENT | S | | | | | |
| | | | DOCUMENT NUMBER | DATE | OFFICE | С | LASS | SUBCLASS | TRAN | ISLATION NO | |
| | | AM | WO 00 56737 | 9/28/00 | PCT | | | | | | |
| | | AN | WO 02 34899 | 5/2/02 | PCT | | | | | | |
| | | AO | WO 98 35056 | 8/13/98 | PCT | | | | | | |
| | | AP | WO 99 38998 | 8/5/99 | PCT | | | | | | |
| | | AQ | WO 99 54286 | 10/28/99 | PCT | | | | | | |

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

Ma et al., "Identification of the binding site for Gqalpha on its effector Bruton's tyrosine kinase", Proc. Natl. Acad. Sci. USA, 95:12197-12201 (1998)

Mahajan et al., "Rational design and synthesis of a novel anti-leukemic agent targeting Bruton's tyrosine kinase (BTK), LFM-A13..", J. Biol. Chem. 274:9587-9599 (1999)

Mano, "Tec family of protein-tyrosine kinases: an overview of their structure and function", Cytokine & Growth Factor Reviews, 10:267-280 (1999)

EXAMINER

DATE CONSIDERED

^{*}EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.

FORM PTO-1449 (REV. 7-85) U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

ATTY. DOCKET NO. D0032 NP APPLICATION NO. 10/045,202 APPLICANT C. Patrick McAtee FILING DATE OCTOBER 22, 2001

Group

| HOW 2 L 2003 F | OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.) | | | | | |
|----------------|--|--|--|--|--|--|
| RADE AA | Roux et al., "Bone loss: factors that regulate osteoclast differentiation: an update", Arthritis Res. 2:451-456 (2000) | | | | | |
| AB | | | | | | |
| AC | · | | | | | |
| AD | | | | | | |
| AE | | | | | | |
| AF | | | | | | |
| AG | | | | | | |
| АН | • | | | | | |
| AI | | | | | | |
| AJ | | | | | | |
| AK | | | | | | |
| . AL | | | | | | |
| АМ | | | | | | |
| AN | | | | | | |
| EXAMINER | DATE CONSIDERED | | | | | |

^{*}EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.